Life Therapeutics (ASX: LFE)(PNK: LFEFY) has signed a new two year contract to produce hyperimmune plasma for a major fractionator. The value of the contract ranges from a minimum of A$4M up to A$12M per year for two years.
Apollo Life Sciences (ASX: AOP), a Sydney-based biotechnology company, is pleased to announce that its topical psoriasis treatment has outperformed current market-leading drugs in preclinical studies. The cream-based treatment, which relieves symptoms without an injection, is now proceeding to Phase 2 clinical trials.
Leading Indonesian pharmaceutical company, Kalbe Farma and CyGenics (ASX: CYN) Officially launch their cord blood bank in Indonesia.
Donor Computer System now rolled out to all Collection Centers ATLANTA - 11 October, 2006 - Life Therapeutics (ASX: LFE) has now successfully completed the computerisation of the 5 West Coast plasma collection centres.
Clinical Cell Culture Ltd (ASX: CCE) today announced that it had entered into a supply agreement with CSL Limited (ASX: CSL) for the supply of Trypsin, a key component of the Company's ReCell(R) tissue harvesting device.
Leading tissue and cord blood banking company CyGenics Ltd. (ASX: CYN) today announced Indonesia's leading pharma company, Kalbe Farma, has taken a 49% stake in its cord blood banking subsidiary, CordLife Indonesia.
Diabetes authority applauds Australian "needle-free treatment" breakthrough One of Australia's top diabetes specialists has praised Sydney-based biotech company Apollo Life Sciences' work to develop an insulin that can be taken as a tablet rather injected, calling needle-free insulin "the Holy Grail" in diabetes treatment.
